ALPER BIOTECH LLC has a total of 32 patent applications. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, measurement and pharmaceuticals are CHIN LI-TE, BIO MATRIX RES INC and SINGH BIOTECHNOLOGY LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 9 | |
#2 | United States | 9 | |
#3 | WIPO (World Intellectual Property Organization) | 9 | |
#4 | Republic of Korea | 2 | |
#5 | Australia | 1 | |
#6 | Canada | 1 | |
#7 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Measurement | |
#3 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Measuring microorganism processes | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Alper Ozge | 18 |
#2 | Alper Özge | 9 |
#3 | Alper •Gze | 1 |
#4 | Alper Oezge | 1 |
#5 | Alper Zge | 1 |
#6 | Alper Õzge | 1 |
Publication | Filing date | Title |
---|---|---|
EP2971047A1 | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof | |
EP2970491A1 | Monoclonal antibodies to egfr, and uses therefor | |
EP2776465A1 | Monoclonal antibodies against serotransferrin antigens, and uses therefor | |
WO2012154957A2 | Diagnosis and prognosis of triple negative breast and ovarian cancer | |
EP2659273A1 | Monoclonal antibodies against alpha-actinin-4 antigens, and uses therefor | |
KR20130048240A | Monoclonal antibodies against pcbp-1 antigens, and uses therefor | |
EP2558501A1 | Monoclonal antibodies against her2 antigens, and uses therefor | |
EP2499160A1 | Monoclonal antibodies against gmf-beta antigens, and uses therefor | |
WO2010080935A1 | Monoclonal antibodies against pcbp-1 antigens, and uses therefor | |
EP2421900A1 | Monoclonal antibodies against pcbp-1 antigens, and uses therefor |